Test Directory

Thrombophilia Profile, Plasma and Whole Blood Updated!

Print this page

Updated Test Information:

  Specimen Type
Last Updated Apr 02, 2021, 10:17 pm
Previous Value Plasma
New Published Value Whole Blood and Plasma
  Specimen Requirements
Last Updated Apr 02, 2021, 10:17 pm
Previous Value Yellow
New Published Value Yellow (ACD) and Na Citrate Plasma
  Specimen Collection / Processing Instructions
Last Updated Apr 02, 2021, 10:17 pm
Previous Value






New Published Value Collection Instructions:
Specimen must be collected prior to factor replacement therapy.
For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing in Special Instructions.
Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
Aliquot plasma (1-2 mL per aliquot) into 5 separate plastic vials leaving 0.25 mL in the bottom of centrifuged vial.
Freeze plasma immediately (no longer than 4 hours after collection) at -20 degrees C or, ideally, <
or =-40 degrees C.
Additional Information:
Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
  Collection File
Last Updated Apr 02, 2021, 10:17 pm
Previous File No previous file.
New File View/Download File
  Additional Information
Last Updated Apr 02, 2021, 10:17 pm
Previous Value

New Published Value 1. Patient should not be receiving Coumadin (warfarin), heparin, direct thrombin inhibitors (argatroban, dabigatran), or direct factor Xa inhibitors (apixaban, rivaroxaban, and edoxaban).
2. Specimen must be collected prior to initiation of anticoagulants and thrombolytic therapy.
3. If patient has been recently transfused, it is best to perform this study pretransfusion, if possible.
  LOINC Code(s)
Last Updated Apr 02, 2021, 10:17 pm
Previous Value
New Published Value
Test Description
Thrombophilia Profile, Plasma and Whole Blood
Synonym(s)

Thrombophilia Prof

Test ID
AATHR
General Information

Useful for:
Evaluating patients with thrombosis or hypercoagulability states
Detecting a lupus-like anticoagulant; dysfibrinogenemia; disseminated intravascular coagulation/intravascular coagulation and fibrinolysis
Detecting a deficiency of antithrombin, protein C, or protein S
Detecting activated protein C resistance (and the factor V R506Q [Leiden] mutation if indicated)
Detecting the prothrombin G20210A mutation

Specimen Type

Whole Blood and Plasma

Specimen Requirements

Yellow (ACD) and Na Citrate Plasma

Specimen Collection / Processing Instructions

Collection Instructions:



  1. Specimen must be collected prior to factor replacement therapy.

  2. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing in Special Instructions.

  3. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.

  4. Aliquot plasma (1-2 mL per aliquot) into 5 separate plastic vials leaving 0.25 mL in the bottom of centrifuged vial.

  5. Freeze plasma immediately (no longer than 4 hours after collection) at -20 degrees C or, ideally, <
    or =-40 degrees C.


Additional Information:


Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.

Collection File View/Download File
Stability

Plasma Na Cit Frozen 14 days
Whole blood Ambient (preferred) 7 days
Frozen 14 days
Refrigerated 14 days

Unacceptable Specimen Conditions

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject

Methodology

PTSC, APTSC, DRV1, TTSC, APCRV: Optical Clot-Based
CLFIB: Clauss
DIMER, PSF,: Latex Immunoassay (LIA)
ATTF, CFX: Chromogenic Assay
PTNT: Direct Mutation Analysis

Estimated TAT

4-7 days

Testing Schedule

Monday-Friday

Test Includes

AATHI Thrombophilia Interpretation
PTSC Prothrombin Time (PT)
APTSC Activated Partial Thrombopl
Time
DRV1 Dilute Russells Viper
Venom Time
TTSC Thrombin Time (Bovine)
CLFIB Fibrinogen, Clauss
DIMER D-Dimer, P Yes
ATTF Antithrombin Activity
CFX P

CPT Code(s)

81240
85300
85303
85306
85307
85379
85384
85390
85610
85613
85670
85730

Additional Information

1. Patient should not be receiving Coumadin (warfarin), heparin, direct thrombin inhibitors (argatroban, dabigatran), or direct factor Xa inhibitors (apixaban, rivaroxaban, and edoxaban).

2. Specimen must be collected prior to initiation of anticoagulants and thrombolytic therapy.

3. If patient has been recently transfused, it is best to perform this study pretransfusion, if possible.

Minimum Sample Volume

Whole Blood: 3 mL
Plasma: 5 mL in 5 polypropylene vials each containing 1 mL

Reference Range

An interpretive report will be provided.

Reflex Conditions

IBETH Bethesda Units
F8IS Coag Factor VIII Assay Inhib Scrn
ATTI Antithrombin Antigen
FACTV Coag Factor V Assay
F_7 Coag Factor VII Assay
F_9 Coag Factor IX Assay
F_10 Coag Factor X Assay
F_11 Coag Factor XI Assay
F_12 Coag Factor XII Assay
F8A Coag Factor VIII Activity Assay
RTSC Reptilase Time
F_2 Coag Factor II Assay
PCAG Protein C Ag
F5DNA Factor V Leiden (R506Q) Mutation
PNP Platelet Neutralization Procedure
PTMSC PT Mix 1:1
APMSC APTT Mix 1:1
PST Protein S Ag
STACL Staclot LA
DRV2 DRVVT Mix
DRV3 DRVVT Confirmation
S_FX Protein S Activity
SOLFM Soluble Fibrin Monomer
PTFIB PT-Fibrinogen

Performing Lab

Mayo

LOINC Code(s)

3255-7, 9049-5, 18771-6, 15359-3, 24475-6, 14979-9, 5902-2, 46717-5, 48067-3, 27811-9, 27818-4, 27821-8, 13590-5, 48591-2, 6301-6, 69049-5, 18771-6